(VIANEWS) – At 15:06 EST on Friday, shares of GENEURO (GNRO.PA) on the CAC 40 index soared 28%, reaching EUR1.44 at 15:06, continuing its upward trajectory from prior sessions. Meanwhile, however, CAC 40 index is currently down 1.17% at EUR7,363.70, signalling an overall downward trend for today’s trading session.
GENEURO closed its last trading session at EUR1.13, which is 67% below its 52-week high of EUR3.48. The recent spike may be related to positive news or developments at GENEURO; however, no details were provided in regard to this matter.
Note that stock prices can be affected by various factors, including company performance, market conditions and economic trends. Therefore, investors should carefully consider these aspects before making investment decisions.
About GENEURO
GeNeuro SA is a biopharmaceutical company with the sole mission of developing treatments for neurodegenerative and autoimmune diseases. Their lead therapeutic candidate, temelimab, is a monoclonal antibody targeting an infectious protein of the HERV-W family and may help treat type 1 diabetes as well as chronic inflammatory demyelinating polyneuropathy. GNK301 is also being developed, while several cooperative research and development agreements with academic centers and the National Institute of Neurological Disorders and Stroke have been entered into to create novel therapeutic antibodies for amyotrophic lateral sclerosis and inflammatory psychosis treatment. GeNeuro holds an agreement with both the International Center for Infectiology Research and Northwestern University to study HERV-W ENV protein expression among long-haul COVID patients. Established in 2006 and located in Plan-les-Ouates Switzerland.
Yearly Analysis
Based on the information provided, GENEURO stock is currently trading at EUR1.44, below its 52-week high of EUR3.48 but above its 52-week low of EUR1.13. This suggests a considerable decline over the past year but recently rebounded from its lowest point.
Be mindful that past performance does not predict future outcomes, and investors must conduct their own analysis and consider other factors before making investment decisions. Furthermore, investors must be mindful of potential risks when investing in GENEURO or any other stock.
Technical Analysis
GENEURO’s current stock price stands at EUR1.91, which is above its 50-day moving average of EUR1.42 but significantly below its 200-day moving average of EUR1.81. This indicates a downward trend over both short- and long-term periods.
Today’s trading volume of 67,070 represents an increase of 496.39% over its average volume of 11,246, suggesting an increased trading activity.
Last week, last month and last quarter the average intraday variation for GENEURO stock was 1.08%; last month was 0.64% and 4.03 %; while 6.86% average volatility persisted between these dates.
Overall, these figures indicate that GENEURO’s stock price has been fluctuating widely, with increased amplitude of volatility seen over the last week and quarter. Investors should keep an eye out for such trends when making investment decisions.
Equity Analysis
Earnings per share (EPS) is a financial metric used to measure how much profit can be attributed to each outstanding share of stock owned by a company. It is calculated by dividing its net income by its outstanding shares.
In the case of GENEURO, their trailing twelve months EPS stands at EUR-0.54; this shows they experienced a net loss per outstanding share totalling EUR-0.54. A negative EPS indicates the company may not currently be profitable and is experiencing financial difficulty.
Investors typically consider earnings per share (EPS) an essential indicator of a company’s financial health and ability to generate profits. A positive EPS indicates profitability, making the company attractive as an investment opportunity, while negative figures should prompt further analysis and caution from investors.
More news about GENEURO (GNRO.PA).
